Half Year Portfolio Review H2 2016

Half Year Portfolio Review H2 2016

In the second half of 2016, I spent very little time on my portfolio. It’s one of the benefits of having a value strategy buying good companies, that you can mostly forget about them. At the start of the half, I was 49% in cash, so I expected to underperform the market by quite a margin. I was pleasantly surprised that my portfolio was up 13.9% in the half, versus 15.1% for the FTSE all share tracker and 8.3% for the S&P tracker. Not bad considering.

The devaluing pound helped some of my positions a lot. I had 28% in foreign holdings at the start, of which 11% was USD which was hedged.

Here are the most significant contributors to my 13.9% gain, sorted by their % affect on my portfolio.

Bloomberg Ticker
Beximco Pharma BXP:LN +3.2%
Ubiquiti Networks UBNT:US +2.7%
Codan Ltd CDA:AU +1.6%
800 Super Holdings ESH:SP +0.8%
Russia 3x tracker RUSL:US +0.7%
Argo ARGO:LN +0.6%
Apple AAPL:US +0.5%
Weiss Korea Opportunity WKOF:LN +0.4%
Softbank SFT:GR +0.4%
Saga Furs SAGCV:FH +0.3%

 

I have already sold Beximco Pharma, and both UBNT and CDA are still short of my fair value estimates. The only negative contributor was Goldplat (GDP:LN) which is still short of my fair value though I haven’t added to the position.

Texhong Textiles ($2678:HK)

I sold this position during the half, but don’t think I reported it. Including dividends and FX movements, it returned 146%, or 53% on an annualised basis. In pure share price terms, it was up 90% on my purchase price. I sold because I thought it had reached about fair value, and I don’t have a great grasp on the business itself to hold long term. Shares are down 6% since I sold.

Gattaca (GATC:LN)

This company was formerly known as Matchtech. This was a new position entered in the half that I didn’t write up. It is a human capital resources business dealing with contract and permanent recruitment in the private and public sectors. It has a strong history of revenue growth (though it acquires) and has recently faltered. There are lots of worries about Brexit as well. It’s at a forward P/E of 7.

This was my portfolio at the end of the year. My up to date portfolio is, as always, on the Portfolio page.

Ticker Size
Cash 41.5%
Weiss Korea Opportunity WKOF:LN 7.1%
Goldplat GDP:LN 6.7%
Beximco Pharma BXP:LN 6.6%
Ubiquiti Networks UBNT:US 6.6%
Pental Ltd PTL:AU 3.8%
Codan Ltd CDA:AU 3.3%
DOM security DOMS:FP 2.8%
United Carpets UCG:LN 2.7%
800 Super Holdings ESH:SP 2.6%
Oracle ORCL:US 2.4%
Apple AAPL:US 2.1%
Argo ARGO:LN 1.9%
Gattaca (formerly Matchtech) GATC:LN 1.7%
Logicamms LCM:AU 1.7%
Softbank SFT:GR 1.7%
Russia 3x tracker RUSL:US 1.4%
Renn RUG:LN 1.0%
Saga Furs SAGCV:FH 1.0%
Awilco Drilling AWDR:NO 0.6%
Hornbeck Offshore HOS:US 0.5%
Avanagrdco AVGR:LI 0.3%

 

In 2017, my main priority will be to put my large cash position to good use, and hope that more Brexit effects come up, like the triggering of article 50, that create some bargain opportunities.

If you found this post useful, please subscribe to receive new posts for free by email.
Or subscribe to the RSS feed.



style="display:block"
data-ad-client="ca-pub-7631902888997793"
data-ad-slot="8013922293"
data-ad-format="auto">

Investing Sidekick

Founder of Investing Sidekick. Works as a research analyst and is an avid value investor, always searching for undervalued shares. An SA certified writer.

2 Responses to Half Year Portfolio Review H2 2016

  1. Mark says:

    Hi what is the thesis on CODAN?

Leave a reply


Disclaimer | Copyright Notice | Terms and Conditions | Privacy Policy | Contact Us

© Copyright 2016 Investing Sidekick. All Rights Reserved.

Pinterest